Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 58
Filter
Add more filters

Country/Region as subject
Publication year range
1.
J Neurosci ; 43(15): 2696-2713, 2023 04 12.
Article in English | MEDLINE | ID: mdl-36894315

ABSTRACT

Although motor cortex is crucial for learning precise and reliable movements, whether and how astrocytes contribute to its plasticity and function during motor learning is unknown. Here, we report that astrocyte-specific manipulations in primary motor cortex (M1) during a lever push task alter motor learning and execution, as well as the underlying neuronal population coding. Mice that express decreased levels of the astrocyte glutamate transporter 1 (GLT1) show impaired and variable movement trajectories, whereas mice with increased astrocyte Gq signaling show decreased performance rates, delayed response times, and impaired trajectories. In both groups, which include male and female mice, M1 neurons have altered interneuronal correlations and impaired population representations of task parameters, including response time and movement trajectories. RNA sequencing further supports a role for M1 astrocytes in motor learning and shows changes in astrocytic expression of glutamate transporter genes, GABA transporter genes, and extracellular matrix protein genes in mice that have acquired this learned behavior. Thus, astrocytes coordinate M1 neuronal activity during motor learning, and our results suggest that this contributes to learned movement execution and dexterity through mechanisms that include regulation of neurotransmitter transport and calcium signaling.SIGNIFICANCE STATEMENT We demonstrate for the first time that in the M1 of mice, astrocyte function is critical for coordinating neuronal population activity during motor learning. We demonstrate that knockdown of astrocyte glutamate transporter GLT1 affects specific components of learning, such as smooth trajectory formation. Altering astrocyte calcium signaling by activation of Gq-DREADD upregulates GLT1 and affects other components of learning, such as response rates and reaction times as well as trajectory smoothness. In both manipulations, neuronal activity in motor cortex is dysregulated, but in different ways. Thus, astrocytes have a crucial role in motor learning via their influence on motor cortex neurons, and they do so by mechanisms that include regulation of glutamate transport and calcium signals.


Subject(s)
Astrocytes , Motor Cortex , Mice , Male , Animals , Female , Astrocytes/metabolism , Motor Cortex/metabolism , Motor Neurons/metabolism , Synaptic Transmission , Amino Acid Transport System X-AG/metabolism
2.
Clin Infect Dis ; 73(11): 2108-2111, 2021 12 06.
Article in English | MEDLINE | ID: mdl-33989390

ABSTRACT

Addressing coronavirus disease 2019 (COVID-19) vaccine hesitancy and minimizing potential vaccine contraindications are critical to combatting the pandemic. We describe a practical approach to immediate adverse events after the first dose of messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2, focusing on diagnosis and management of allergic reactions.


Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19 Vaccines , Humans , Vaccination Hesitancy , mRNA Vaccines
3.
Ann Allergy Asthma Immunol ; 126(4): 338-349, 2021 04.
Article in English | MEDLINE | ID: mdl-33307158

ABSTRACT

OBJECTIVE: To provide an overview of the literature on respiratory infectious disease epidemic prediction, preparedness, and response (including pharmaceutical and nonpharmaceutical interventions) and their impact on public health, with a focus on respiratory conditions such as asthma. DATA SOURCES: Published literature obtained through PubMed database searches. STUDY SELECTIONS: Studies relevant to infectious epidemics, asthma, modeling approaches, health care access, and data analytics related to intervention strategies. RESULTS: Prediction, prevention, and response strategies for infectious disease epidemics use extensive data sources and analytics, addressing many areas including testing and early diagnosis, identifying populations at risk of severe outcomes such as hospitalizations or deaths, monitoring and understanding transmission and spread patterns by age group, social interactions geographically and over time, evaluating the effectiveness of pharmaceutical and nonpharmaceutical interventions, and understanding prioritization of and access to treatment or preventive measures (eg, vaccination, masks), given limited resources and system constraints. CONCLUSION: Previous epidemics and pandemics have revealed the importance of effective preparedness and response. Further research and implementation need to be performed to emphasize timely and actionable strategies, including for populations with particular health conditions (eg, chronic respiratory diseases) at risk for severe outcomes.


Subject(s)
Pandemics/prevention & control , Respiratory Tract Infections/prevention & control , Humans , Public Health/methods , Respiratory Tract Infections/epidemiology
4.
Allergy ; 75(2): 259-272, 2020 02.
Article in English | MEDLINE | ID: mdl-31230373

ABSTRACT

Mobile health (mHealth) uses mobile communication devices such as smartphones and tablet computers to support and improve health-related services, data and information flow, patient self-management, surveillance, and disease management from the moment of first diagnosis to an optimized treatment. The European Academy of Allergy and Clinical Immunology created a task force to assess the state of the art and future potential of mHealth in allergology. The task force endorsed the "Be He@lthy, Be Mobile" WHO initiative and debated the quality, usability, efficiency, advantages, limitations, and risks of mobile solutions for allergic diseases. The results are summarized in this position paper, analyzing also the regulatory background with regard to the "General Data Protection Regulation" and Medical Directives of the European Community. The task force assessed the design, user engagement, content, potential of inducing behavioral change, credibility/accountability, and privacy policies of mHealth products. The perspectives of healthcare professionals and allergic patients are discussed, underlining the need of thorough investigation for an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the context of precision medicine, these could facilitate the change in perspective from clinician- to patient-centered care. The current and future potential of mHealth is then examined for specific areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of mobile technologies and associated big data sets are outlined. Facts and recommendations for future mHealth initiatives within EAACI are listed.


Subject(s)
Anaphylaxis/therapy , Asthma/therapy , Chronic Urticaria/therapy , Dermatitis, Allergic Contact/therapy , Dermatitis, Atopic/therapy , Drug Hypersensitivity/therapy , Food Hypersensitivity/therapy , Rhinitis, Allergic, Seasonal/therapy , Telemedicine/methods , Desensitization, Immunologic/methods , Disease Management , Humans , Mobile Applications , Physician-Patient Relations
5.
Curr Allergy Asthma Rep ; 20(5): 14, 2020 04 20.
Article in English | MEDLINE | ID: mdl-32314071

ABSTRACT

PURPOSE OF THE REVIEW: Peanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments. RECENT FINDINGS: The latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions. Future research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.


Subject(s)
Arachis/immunology , Desensitization, Immunologic/methods , Peanut Hypersensitivity/therapy , Administration, Oral , Humans , Immunoglobulin E/blood , Peanut Hypersensitivity/immunology , Quality of Life , Treatment Outcome
6.
Curr Allergy Asthma Rep ; 19(1): 1, 2019 01 19.
Article in English | MEDLINE | ID: mdl-30661123

ABSTRACT

PURPOSE OF REVIEW: Telemedicine uses technology to connect patients and data with providers at a distance. Direct to consumer telemedicine is a rapidly growing segment of the industry. RECENT FINDINGS: The telehealth market has skyrocketed in recent years, making it a multi-billion dollar industry. Direct to consumer telehealth, dominated by the for-profit private sector, is the most popular form. Direct to consumer telemedicine is a subset of telehealth that shows promise in increasing access to and engagement in medical care. Quality assurance, reimbursement, and regulatory oversight are important factors in assuring appropriate widespread adoption.


Subject(s)
Telemedicine , Humans
7.
Allergy Asthma Proc ; 40(1): 57-61, 2019 01 01.
Article in English | MEDLINE | ID: mdl-30582497

ABSTRACT

Introduction: Ten percent of hospitalized patients report penicillin allergy; however, recent studies indicate that ∼98% of these patients are not acutely hypersensitive. Unconfirmed penicillin allergy poses public health risks, and an evaluation of penicillin allergy labels is recommended to improve antibiotic stewardship. Although the most widely accepted protocol is penicillin skin testing, followed by oral amoxicillin challenge, time constraints and resources may preclude this. Recent literature supports the safety and efficacy of direct oral amoxicillin challenge in individuals at low risk. Methods: We retrospectively evaluated direct oral challenge acceptance and outcomes in eligible adult outpatients with allergy and with a penicillin allergy label over a 6-month period. Direct oral amoxicillin challenge was recommended in patients with a history of benign rash, benign somatic symptoms, or unknown history associated with the last penicillin exposure >12 months ago. Those with severe reactions or reactions within 12 months of evaluation were not challenged. The patients were monitored for 60 minutes after challenge and were discharged with instructions to call in the event of a delayed reaction. Results: There were 50 of 355 adults (14%) with a penicillin allergy label seen by a single allergist; of these patients, 38 (76%) met our criteria for a direct oral challenge. The index penicillin associated reactions were mostly remote, and 44 subjects (88%) reported reactions >10 years earlier. Four patients (8%) were de-labeled based on history alone. Twenty subjects (40%) consented to challenge in the clinic, and none developed immediate, or to our knowledge, delayed hypersensitivity reactions. Three of 20 patients (15%) developed self-limited subjective symptoms that were not deemed to constitute true immunoglobulin E mediated hypersensitivity. A total of 24 patients (48%) had the penicillin allergy label removed from their medical record. Conclusion: This study added to the accumulating body of evidence that supports the safety and efficacy of direct provocative challenge without preliminary skin testing to exclude penicillin allergy in individuals at low risk. Larger prospective studies are necessary to confirm these observations.


Subject(s)
Amoxicillin/administration & dosage , Anti-Bacterial Agents/adverse effects , Drug Hypersensitivity/epidemiology , Penicillins/adverse effects , Adult , Amoxicillin/adverse effects , Anti-Bacterial Agents/administration & dosage , Bronchial Provocation Tests , Drug Hypersensitivity/diagnosis , Female , Humans , Male , Patient Outcome Assessment , Risk Assessment , Risk Factors , Severity of Illness Index , Skin Tests , Symptom Assessment
8.
Curr Allergy Asthma Rep ; 18(10): 50, 2018 08 15.
Article in English | MEDLINE | ID: mdl-30112587

ABSTRACT

PURPOSE OF REVIEW: Telemedicine is a technology that permits patients to be seen at a distance. This review describes different types of telemedicine, why they might be useful for a practice, what equipment is needed, and how to select and schedule patients. RECENT FINDINGS: The use of synchronous telemedicine is increasing rapidly and has surpassed 50% of ambulatory encounters in some instances. Management of patients is particularly germane for an allergy practice since it is an outpatient specialty with patients who live in widely distributed locations with limited access to allergists. With utilization of digital exam equipment, in vitro tests for diagnosis, and spirometry at the patient location, there are few clear advantages of seeing patients in-person over virtual visits. Telemedicine is here today. As its use increases, it is critical that allergy specialists embrace this new technology.


Subject(s)
Telemedicine , Humans , Hypersensitivity/diagnosis , Hypersensitivity/therapy
9.
Ann Allergy Asthma Immunol ; 119(6): 512-517, 2017 12.
Article in English | MEDLINE | ID: mdl-29103799

ABSTRACT

The integration of telecommunications and information systems in health care first began 4 decades ago with 500 patient consultations performed via interactive television. The use of telemedicine services and technology to deliver health care at a distance is increasing exponentially. Concomitant with this rapid expansion is the exciting ability to provide enhancements in quality and safety of care. Telemedicine enables increased access to care, improvement in health outcomes, reduction in medical costs, better resource use, expanded educational opportunities, and enhanced collaboration between patients and physicians. These potential benefits should be weighed against the risks and challenges of using telemedicine. The American College of Allergy, Asthma, and Immunology advocates for incorporation of meaningful and sustained use of telemedicine in allergy and immunology practice. This article serves to offer policy and position statements of the use of telemedicine pertinent to the allergy and immunology subspecialty.


Subject(s)
Referral and Consultation , Remote Consultation/statistics & numerical data , Videoconferencing/statistics & numerical data , Allergists , Humans , Patient Satisfaction , Physician-Patient Relations , Remote Consultation/economics , United States , Videoconferencing/economics
10.
J Natl Compr Canc Netw ; 13(8): 947-52, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26285240

ABSTRACT

Next-generation sequencing of primary and metachronous metastatic cancer lesions may impact patient care. We present a case of relapsed metastatic breast cancer with a dominant pulmonary lesion originally identified as lung adenocarcinoma. A 72-year-old, never-smoker woman with a protracted cough was found to have a large lung mass and regional lymphadenopathy on a chest CT. Lung mass biopsy showed adenocarcinoma with focal TTF-1 (thyroid transcription factor 1) positivity, favoring a lung primary. In addition to stereotactic brain radiation for cerebral metastases, she was started on carboplatin/pemetrexed. As part of the workup, the tumor was analyzed by a 50-gene targeted mutation panel, which detected 3 somatic mutations: ERBB2 (HER2) D769H activating missense mutation, TP53 Y126 inactivating truncating mutation, and SMARCB1 R374Q missense mutation. Of note, the patient had a history of stage IIA triple-negative grade 3 invasive ductal carcinoma of the left breast 1.5 years ago and received neoadjuvant chemotherapy and adjuvant radiation, and underwent a lumpectomy. Further analysis of her primary breast tumor showed a mutational profile identical to that of the lung tumor. Fluorescence in situ hybridization revealed HER2 amplification in the lung tumor, with a HER2/CEP17 ratio of 3.9. The patient was diagnosed with recurrent HER2-positive metastatic breast carcinoma with a coexisting ERBB2 (HER2) activating mutation. Chemotherapy was adjusted to include dual HER2-targeted therapy containing trastuzumab and pertuzumab, resulting in an ongoing partial response. This case demonstrates that a unique genetic mutational profile can clarify whether a tumor represents a metastatic lesion or new malignancy when conventional morphological and immunohistochemical methods are indeterminate, and can directly impact treatment decisions.


Subject(s)
Breast Neoplasms/genetics , Gene Amplification , Mutation , Receptor, ErbB-2/genetics , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Brain Neoplasms/diagnosis , Brain Neoplasms/secondary , Brain Neoplasms/therapy , Breast Neoplasms/diagnosis , Breast Neoplasms/drug therapy , Female , Genetic Testing , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/therapy , Neoplasm Staging , Neoplasms, Second Primary , Radiography, Thoracic , Radiosurgery , Tomography, X-Ray Computed , Treatment Outcome
12.
Curr Heart Fail Rep ; 12(3): 263-8, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25895034

ABSTRACT

Idiopathic giant cell myocarditis (IGCM) is a rare disease causing progressive myocarditis characterized by myocardial necrosis and giant cells. Patients often present with rapidly progressive heart failure, ventricular arrhythmias, and heart block. Without treatment, the disease often results in progressive pump failure requiring urgent cardiac transplantation or the need for mechanical circulatory support. The underlying pathophysiologic mechanisms are not yet defined but appear to involve genetics, autoimmune disorders, and possibly environmental factors such as viruses. Combined immunosuppressive regimens appear to prolong survival from death or cardiac transplant. Nevertheless, cardiac transplant is an effective treatment. The disease can recur in the transplanted heart resulting in death or the need for retransplant.


Subject(s)
Giant Cells/pathology , Myocarditis/diagnosis , Cardiovascular Agents/therapeutic use , Heart Transplantation , Heart-Assist Devices , Humans , Myocarditis/epidemiology , Myocarditis/physiopathology , Myocarditis/therapy , Rare Diseases/diagnosis , Rare Diseases/epidemiology , Rare Diseases/physiopathology , Rare Diseases/therapy
14.
J Neurochem ; 131(5): 573-81, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25196144

ABSTRACT

Glutamate transport is a critical process in the brain that maintains low extracellular levels of glutamate to allow for efficient neurotransmission and prevent excitotoxicity. Loss of glutamate transport function is implicated in epilepsy, traumatic brain injury, and amyotrophic lateral sclerosis. It remains unclear whether or not glutamate transport can be modulated in these disease conditions to improve outcome. Here, we show that sirtuin (SIRT)4, a mitochondrial sirtuin, is up-regulated in response to treatment with the potent excitotoxin kainic acid. Loss of SIRT4 leads to a more severe reaction to kainic acid and decreased glutamate transporter expression and function in the brain. Together, these results indicate a critical and novel stress response role for SIRT4 in promoting proper glutamate transport capacity and protecting against excitotoxicity.


Subject(s)
Excitatory Amino Acid Agonists/pharmacology , Excitatory Amino Acid Transporter 2/metabolism , Gene Expression Regulation/drug effects , Glutamic Acid/metabolism , Kainic Acid/pharmacology , Mitochondrial Proteins/deficiency , Sirtuins/deficiency , Animals , Biotinylation , Brain/cytology , Brain/drug effects , Cells, Cultured , Disease Models, Animal , Embryo, Mammalian , Female , Male , Mice , Mice, Knockout , Neurons/drug effects , Neurons/ultrastructure , Seizures/chemically induced , Seizures/pathology , Synaptosomes/drug effects , Synaptosomes/metabolism
16.
Biol Psychiatry ; 93(1): 71-81, 2023 01 01.
Article in English | MEDLINE | ID: mdl-36372569

ABSTRACT

BACKGROUND: Fragile X syndrome (FXS) is characterized by physical abnormalities, anxiety, intellectual disability, hyperactivity, autistic behaviors, and seizures. Abnormal neuronal development in FXS is poorly understood. Data on patients with FXS remain scarce, and FXS animal models have failed to yield successful therapies. In vitro models do not fully recapitulate the morphology and function of human neurons. METHODS: To mimic human neuron development in vivo, we coinjected neural precursor cells derived from FXS patient-derived induced pluripotent stem cells and neural precursor cells derived from corrected isogenic control induced pluripotent stem cells into the brain of neonatal immune-deprived mice. RESULTS: The transplanted cells populated the brain and a proportion differentiated into neurons and glial cells. Immunofluorescence and single and bulk RNA sequencing analyses showed accelerated maturation of FXS neurons after an initial delay. Additionally, we found increased percentages of Arc- and Egr-1-positive FXS neurons and wider dendritic protrusions of mature FXS striatal medium spiny neurons. CONCLUSIONS: This transplantation approach provides new insights into the alterations of neuronal development in FXS by facilitating physiological development of cells in a 3-dimensional context.


Subject(s)
Fragile X Syndrome , Neural Stem Cells , Humans , Mice , Animals , Fragile X Syndrome/genetics , Fragile X Mental Retardation Protein/genetics , Fragile X Mental Retardation Protein/metabolism , Neural Stem Cells/metabolism , Neurons/metabolism , Phenotype , Brain/metabolism , Mice, Knockout
17.
Anesthesiology ; 116(3): 586-602, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22354242

ABSTRACT

BACKGROUND: Anesthesia given to immature rodents causes cognitive decline, raising the possibility that the same might be true for millions of children undergoing surgical procedures under general anesthesia each year. We tested the hypothesis that anesthesia-induced cognitive decline in rats is treatable. We also tested if anesthesia-induced cognitive decline is aggravated by tissue injury. METHODS: Seven-day old rats underwent sevoflurane anesthesia (1 minimum alveolar concentration, 4 h) with or without tail clamping. At 4 weeks, rats were randomized to environmental enrichment or normal housing. At 8 weeks rats underwent neurocognitive testing, which consisted of fear conditioning, spatial reference memory, and water maze-based memory consolidation tests, and interrogated working memory, short-term memory, and early long-term memory. RESULTS: Sevoflurane-treated rats had a greater escape latency when the delay between memory acquisition and memory retrieval was increased from 1 min to 1 h, indicating that short-term memory was impaired. Delayed environmental enrichment reversed the effects of sevoflurane on short-term memory and generally improved many tested aspects of cognitive function, both in sevoflurane-treated and control animals. The performance of tail-clamped rats did not differ from those rats receiving anesthesia alone. CONCLUSION: Sevoflurane-induced cognitive decline in rats is treatable. Delayed environmental enrichment rescued the sevoflurane-induced impairment in short-term memory. Tissue injury did not worsen the anesthesia-induced memory impairment. These findings may have relevance to neonatal and pediatric anesthesia.


Subject(s)
Housing, Animal , Memory Disorders/chemically induced , Memory Disorders/therapy , Methyl Ethers/toxicity , Age Factors , Animals , Animals, Newborn , Male , Maze Learning/drug effects , Maze Learning/physiology , Memory Disorders/physiopathology , Random Allocation , Rats , Rats, Sprague-Dawley , Sevoflurane , Time Factors
18.
Nat Med ; 11(1): 95-101, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15619629

ABSTRACT

Molecular profiling of human biopsies and surgical specimens is frequently complicated by their inherent biological heterogeneity and by the need to conserve tissue for clinical diagnosis. We have developed a set of novel 'tissue print' and 'print-phoresis' technologies to facilitate tissue and tumor-marker profiling under these circumstances. Tissue printing transfers cells and extracellular matrix components from a tissue surface onto nitrocellulose membranes, generating a two-dimensional anatomical image on which molecular markers can be visualized by specific protein and RNA- and DNA-detection techniques. Print-phoresis is a complementary new electrophoresis method in which thin strips from the print are subjected to polyacrylamide gel electrophoresis, providing a straightforward interface between the tissue-print image and gel-based proteomic techniques. Here we have utilized these technologies to identify and characterize markers of tumor invasion of the prostate capsule, an event generally not apparent to the naked eye that may result in tumor at the surgical margins ('positive margins'). We have also shown that tissue-print technologies can provide a general platform for the generation of marker maps that can be superimposed directly onto histopathological and radiological images, permitting molecular identification and classification of individual malignant lesions.


Subject(s)
Prostatic Neoplasms/diagnosis , Proteins , Biomarkers , Humans , Male , Prostate/metabolism , Prostate/pathology , Prostatic Neoplasms/metabolism , Proteins/metabolism
19.
Biotechnol Lett ; 34(8): 1453-8, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22481299

ABSTRACT

We have developed a perfusion-based high cell density (HD) cell banking and inoculum expansion procedure for a cholesterol-dependent NS0 myeloma cell line using linear low-density polyethylene-based disposable bioreactors. Challenges associated with cholesterol-polymer interactions, which suppress cholesterol-dependent NS0 myeloma cell growth, were overcome using a novel cholesterol feeding protocol that included a combination of two cholesterol formulations: an ethanol-based formulation and an aqueous formulation. Using a cholesterol feed optimized for HD cell culture in a disposable bioreactor perfusion system, cell densities of >25 × 10(6) viable cells/ml at ≥ 90 % cell viability were achieved. Vials of high density cell banks were created by filling 90-100 × 10(6) viable cells/ml in 5 ml cryotube vials. Implementation of the HD cell banks enabled a significant reduction in the number of step operations in the inoculum expansion phase in a large-scale manufacturing setting.


Subject(s)
Bioreactors , Cell Culture Techniques/methods , Cholesterol/metabolism , Polyethylene , Animals , Cell Culture Techniques/instrumentation , Cell Line, Tumor , Cell Survival , Cholesterol/chemistry , Culture Media/chemistry , Culture Media/metabolism , Ethanol/chemistry , Ethanol/metabolism , Kinetics , Mice
20.
J Allergy Clin Immunol Pract ; 10(10): 2514-2523, 2022 10.
Article in English | MEDLINE | ID: mdl-36038132

ABSTRACT

The COVID-19 pandemic created an explosion in the use of telehealth. However, telehealth consists of much more than a video discussion between doctor and patient. Since the onset of the COVID-19 pandemic, allergists have demonstrated a high level of synchronous telemedicine adoption with existing patients but have not taken full advantage of other virtual care modalities that have the potential to facilitate the efficient delivery of allergy care to the broader population. This is partially due to a lack of awareness about the various remote care services and how to implement and bill for them appropriately. This rostrum describes the spectrum of telehealth services, reviews existing literature on the use of telehealth in allergy, and provides suggestions about how allergists and immunologists can optimize the use of telehealth to optimize patient access and outcomes as well as receive appropriate compensation for specialty clinical services provided by themselves and their staff.


Subject(s)
COVID-19 , Hypersensitivity , Telemedicine , Delivery of Health Care , Humans , Hypersensitivity/epidemiology , Hypersensitivity/therapy , Pandemics
SELECTION OF CITATIONS
SEARCH DETAIL